Year-end Sale % OFF 
Abstract
We carried out this systemic review and meta-analysis of relevant randomized controlled trials to determine different dosage regimens of vardenafil in the treatment of male erectile dysfunction (ED). Using appropriate keywords, we searched PubMed, the Cochrane Library, and Embase for relevant literature before March 2020. We evaluated odds ratio (OR), weighted mean difference (WMD), and 95% confidence interval (95% CI) to assess the results of each study. We included 14 studies with a total of 3221 patients. Compared with the placebo, vardenafil significantly increased International Erectile Function Index (IIEF) overall satisfaction (WMD 3.37, 95%CI 2.02-4.71), IIEF-erectile function (WMD 7.93, 95%CI 6.00-9.85), IIEF sexual desire (WMD 0.79, 95%CI 0.24-1.35), IIEF intercourse satisfaction (WMD 5.24, 95%CI 3.35-7.13), IIEF orgasmic function (WMD 3.81, 95%CI 2.26-5.35), Sexual Encounter Profile (SEP) Q2 (WMD 26.36, 95%CI 22.95-29.77), and SEP Q3 (WMD 35.18, 95%CI 31.89-38.48). Vardenafil demonstrated significant efficacy in the treatment of ED, but the optimal dose and course of vardenafil remain to be established.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
